Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Reduce” from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have received a consensus recommendation of “Reduce” from the thirteen research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $38.9167.

Several research analysts have issued reports on HIMS shares. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. UBS Group set a $30.00 price target on Hims & Hers Health in a research note on Monday, June 23rd. Finally, Truist Financial reduced their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at approximately $9,105,385.20. This trade represents a 26.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the sale, the chief executive officer directly owned 89,521 shares of the company’s stock, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,110,347 shares of company stock worth $55,342,532 in the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HIMS. BNP Paribas Financial Markets bought a new position in Hims & Hers Health during the fourth quarter valued at $1,230,000. Captrust Financial Advisors purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $340,000. Cetera Investment Advisers grew its stake in shares of Hims & Hers Health by 11.1% during the 4th quarter. Cetera Investment Advisers now owns 14,628 shares of the company’s stock worth $354,000 after acquiring an additional 1,466 shares during the period. Gotham Asset Management LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth about $440,000. Finally, Janus Henderson Group PLC raised its stake in Hims & Hers Health by 17.3% in the 4th quarter. Janus Henderson Group PLC now owns 80,069 shares of the company’s stock valued at $1,936,000 after acquiring an additional 11,800 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $50.83 on Wednesday. The company has a 50 day moving average of $50.41 and a 200-day moving average of $45.40. The company has a market cap of $11.49 billion, a PE ratio of 63.54, a price-to-earnings-growth ratio of 3.64 and a beta of 2.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health has a 1-year low of $15.73 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.